Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A 2
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …

BACKGROUND: The absolute risk of recurrences among patients using aspirin for
prevention of cardiovascular events remains high. Persistent platelet reactivity despite …

Background: Antiplatelet agents such as acetylsalicylic acid (aspirin) reduce the relative risk
for cerebrovascular events in patients with cardiovascular or cerebrovascular disorders by …

Aspirin is currently the most cost-effective drug for the secondary prevention of
cardiovascular disease, but treatment failures are relatively common. Several factors have …

Cyclooxygenase-1 [COX-1, prostaglandin synthase] catalyses the transformation of
arachidonic acid to the unstable intermediate prostaglandin PGH2. Subsequently …

Aspirin is the most commonly used therapeutic agent in prevention of vascular ischemic
events. Aspirin exerts its antithrombotic effect primarily by interfering with the biosynthesis of …

Treatment failures occur with any drug and aspirin is no exception. Evidence is growing to
indicate that there are subpopulations that do not respond to antithrombotic action of aspirin …

Introduction: Aspirin resistance is associated with increased cardiovascular risk in aspirin‐
treated patients. Poor compliance may explain many cases of “resistance,” yet few clinical …

Aspirin (acetylsalicylic acid) reduces the odds of serious atherothrombotic vascular events
and death in a broad category of high risk patients by about one-quarter. The mechanism is …

BACKGROUND: Aspirin resistance appears to be an important prognostic factor in patients
with coronary artery disease, yet there is no standardized method to measure it and limited …